Frontiers in Medicine (Jun 2021)

Investigation of Coagulation Biomarkers to Assess Clinical Deterioration in SARS-CoV-2 Infection

  • Paul Billoir,
  • Paul Billoir,
  • Kevin Alexandre,
  • Thomas Duflot,
  • Maxime Roger,
  • Sébastien Miranda,
  • Sébastien Miranda,
  • Odile Goria,
  • Luc Marie Joly,
  • Mathieu Demeyere,
  • Guillaume Feugray,
  • Valery Brunel,
  • Manuel Etienne,
  • Véronique Le Cam Duchez

DOI
https://doi.org/10.3389/fmed.2021.670694
Journal volume & issue
Vol. 8

Abstract

Read online

Since December 2019, a pandemic caused by a new coronavirus has spread to more than 170 countries around the world. Worsening infected patients requiring intensive care unit (ICU) admission associated with 30% of mortality. A part of worsening is induced by hemostasis deregulation. The aim of this study was to investigate the association of coagulation activation in COVID-19 progression. Thirty-five of the 99 patients got clinically worse. The final model of the logistic regression analysis revealed that O2 requirement (RR = 7.27 [1.50–19.31]), monocytes below 0.2G/L (RR = 2.88 [1.67–3.19]), fibrinogen levels (RR = 1.45 [1.17–1.82] per g/L increase), prothrombin fragments 1+2 higher than 290 pM (RR = 2.39 [1.20–3.30]), and thrombin peak (RR = 1.28 [1.03–1.59] per 50 nM increase) were associated with an increased risk of clinical worsening. A fibrinogen level threshold of 5.5 g/L, a thrombin peak measurement threshold of 99 pM, and O2 requirement associated with clinical outcome in more than 80% of our cohort. In conclusion, we identified fibrinogen and thrombin peak at admission as coagulation biomarkers associated with an increased risk of ICU admission or death. This finding allows initiating steroids and triage for worsening patients. Our results should therefore be considered as exploratory and deserve confirmation.

Keywords